Kura Oncology, Inc. (KURA)
Automate Your Wheel Strategy on KURA
With Tiblio's Option Bot, you can configure your own wheel strategy including KURA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol KURA
- Rev/Share 0.7778
- Book/Share 4.1687
- PB 1.3649
- Debt/Equity 0.0531
- CurrentRatio 8.0676
- ROIC -0.314
- MktCap 492610043.0
- FreeCF/Share 1.2647
- PFCF 4.4558
- PE -2.7346
- Debt/Assets 0.026
- DivYield 0
- ROE -0.4362
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 3
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | KURA | BTIG Research | Buy | Neutral | -- | -- | Feb. 6, 2025 |
| Downgrade | KURA | Stifel | Buy | Hold | $26 | $19 | Oct. 14, 2024 |
News
Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML
Published: June 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
– New Drug Application based on positive results from the Phase 2 KOMET-001 trial – – FDA assigns a Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2025 – – Potential first approval of a menin inhibitor for the treatment of adult patients with relapsed or refractory AML with an NPM1 mutation – SAN DIEGO and TOKYO, June 01, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA, “Kura”) and Kyowa Kirin Co., Ltd. (TSE: 4151, “Kyowa Kirin”) today announced the U.S. Food and Drug Administration (FDA) has accepted Kura's New Drug Application (NDA) seeking full …
Read More
Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting
Published: May 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
– Results from KOMET-001 registration-directed trial of ziftomenib in R/R NPM1-m AML patients selected for oral presentation on Monday, June 2nd –
Read More
Kura Oncology and Kyowa Kirin Announce Combination Data for Ziftomenib in Oral Presentation at the 2025 European Hematology Association (EHA) Congress
Published: May 14, 2025 by: GlobeNewsWire
Sentiment: Neutral
– Ziftomenib combined with 7+3 in 1L NPM1-m or KMT2A-r AML patients selected for oral presentation on Thursday, June 12th –
Read More
Kura Oncology to Participate in Bank of America Securities Healthcare Conference
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, May 06, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in Bank of America Securities 2025 Healthcare Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a fireside chat at 6:00 p.m. ET / 3:00 p.m. PT on May 13, 2025. A live audio webcast of the fireside chat will be available in the Investors section of Kura's website at www.kuraoncology.com, with an archived replay following the event.
Read More
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: April 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, April 04, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on April 1, 2025, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 79,500 shares of common stock to four (4) new employees under the Company's 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listing …
Read More
Kura Oncology, Inc. (KURA) Q4 2024 Earnings Call Transcript
Published: February 27, 2025 by: Seeking Alpha
Sentiment: Neutral
Kura Oncology, Inc. (NASDAQ:KURA ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Patti Bank - IR Troy Wilson - President and CEO Mollie Leoni - CMO Tom Doyle - SVP of Finance and Accounting Brian Powl - CCO Conference Call Participants Li Watsek - Cantor Fitzgerald Yen-Der Li - Leerink Partners Jason Zemansky - Bank of America Peter Lawson - Barclays Dara Azar - Stifel Charles Zhu - LifeSci Capital David Dai - UBS Justin Zelin - BTIG George Farmer - Scotiabank Operator Good day, everyone, and welcome to today's Q4 2024 Kura Oncology, …
Read More
Kura Oncology (KURA) Reports Q4 Loss, Lags Revenue Estimates
Published: February 26, 2025 by: Zacks Investment Research
Sentiment: Negative
Kura Oncology (KURA) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to loss of $0.55 per share a year ago.
Read More
Kura Oncology Reports Fourth Quarter and Full Year 2024 Financial Results
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
– KOMET-001 registrational trial in R/R NPM1-mutant AML achieved primary endpoint – – Alignment reached with FDA and EMA on key aspects of the KOMET-017 protocol including use of MRD-negative CR endpoint for potential U.S. accelerated approval pathway in frontline intensive chemotherapy trial – – Topline MRD-negative CR results from KOMET-017-IC Phase 3 trial anticipated in 2028 – – Multiple data presentations for ziftomenib and pipeline programs expected throughout 2025 – – $727.4 million in cash, together with anticipated collaboration agreement payments, to support ziftomenib commercialization through the frontline AML combination setting – – Management to host webcast and conference …
Read More
About Kura Oncology, Inc. (KURA)
- IPO Date 2015-09-16
- Website https://kuraoncology.com
- Industry Biotechnology
- CEO Dr. Troy Edward Wilson J.D., Ph.D.
- Employees 192